Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


J Am Soc Nephrol 16: 67-69, 2005
© 2005 American Society of Nephrology
doi: 10.1681/ASN.2004110959
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Casadevall, N.
Right arrow Articles by Rossert, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Casadevall, N.
Right arrow Articles by Rossert, J.

Epoetin-Induced Autoimmune Pure Red Cell Aplasia

Nicole Casadevall*, Kai-Uwe Eckardt{dagger} and Jérôme Rossert{ddagger}

* Department of Hematology, Hotel Dieu and INSERM U362, Paris, France; {dagger} Division of Nephrology and Hypertension, University of Erlangen-Nuremberg, Erlangen, Germany; and {ddagger} Department of Nephrology, Tenon Hospital (AP-HP) and Pierre and Marie Curie University, Paris, France

Address correspondence to: Dr. Nicole Casadevall, Department of Hematology, Hotel Dieu, 1 place du Parvis de Notre Dame, 75004 Paris, France. Phone: +33–132-348266; Fax: +33–142-348254; E-mail: nicole.casadevall{at}htd.ap-hop-paris.fr

During the first 10 yr of therapy with recombinant human erythropoietin ([EPO]), only three cases of antibody-associated pure red cell aplasia have been described in patients who were treated with EPO, whereas several millions of patients have received this treatment. Thus, the possibility for epoetin to induce the formation of anti-EPO antibodies was considered extremely low. However, since 1998, a significant increase in the number of cases of EPO-induced pure red cell aplasia has been found in patients with chronic kidney disease with a peak in 2001 and 2002. The incidence rate seems now to be back to the baseline level. The change in formulation of epoetin {alpha} sold outside the United States seems to be the cause of these antibodies.




This article has been cited by other articles:


Home page
 NDT PlusHome page
J. Assuncao and J. Vinhas
Antibody-mediated pure red cell aplasia (PRCA) on switching from darbepoetin alfa to epoetin beta: what are the implications?
NDT Plus, August 1, 2008; 1(4): 230 - 232.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673